Anker, Stefan D.

ESC e-Cardiology Working Group Position Paper: Overcoming challenges in digital health implementation in cardiovascular medicine

Frederix, I., Caiani, E. G., Dendale, P., Anker, S., Bax, J., Böhm, A., Cowie, M., Crawford, J., de Groot, N., Dilaveris, P., et al. (2019) · European Journal of Preventive Cardiology

Mobile Health and mHealth ApplicationsTelemedicine and Telehealth Implementation

Cited by 323

Multicomponent intervention to prevent mobility disability in frail older adults: randomised controlled trial (SPRINTT project)

Bernabei, R., Landi, F., Calvani, R., Cesari, M., Del Signore, S., Anker, S. D., Bejuit, R., Bordes, P., Cherubini, A., Cruz-Jentoft, A. J., et al. (2022) · BMJ

Frailty in Older AdultsNutrition and Health in Aging

Cited by 318

Finerenone Reduces Risk of Incident Heart Failure in Patients With Chronic Kidney Disease and Type 2 Diabetes: Analyses From the FIGARO-DKD Trial

Filippatos, G., Anker, S. D., Agarwal, R., Ruilope, L. M., Rossing, P., Bakris, G. L., Tasto, C., Joseph, A., Kolkhof, P., Lage, A., et al. (2022) · Circulation

Chronic Kidney Disease and DiabetesHeart Failure Treatment and Management

Cited by 299

Finerenone and cardiovascular outcomes in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Anker, S. D., Agarwal, R., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Schloemer, P., Tornus, I., Joseph, A., et al. (2021) · Circulation

Chronic Kidney Disease and DiabetesHormonal Regulation and Hypertension

Cited by 294

Impaired insulin sensitivity as an independent risk factor for mortality in patients with stable chronic heart failure

Doehner, W., Rauchhaus, M., Ponikowski, P., Godsland, I. F., von Haehling, S., Okonko, D. O., Leyva, F., Proudler, A. J., Coats, A. J. S., & Anker, S. D. (2005) · Journal of the American College of Cardiology

Heart Failure Treatment and ManagementDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 294

. Effects of serelaxin in patients with acute heart failure

Metra, M., Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., Pang, P. S., Ponikowski, P., Voors, A. A., et al. (2019) · New England Journal of Medicine

Heart Failure Treatment and ManagementPregnancy-related medical research

Cited by 282

Iron Deficiency Predicts Impaired Exercise Capacity in Patients With Systolic Chronic Heart Failure

Jankowska, E. A., Rozentryt, P., Witkowska, A., Nowak, J., Hartmann, O., Ponikowska, B., Borodulin-Nadzieja, L., von Haehling, S., Doehner, W., Banasiak, W., et al. (2011) · Journal of Cardiac Failure

Cardiovascular and exercise physiologyIron Metabolism and Disorders

Cited by 281

The importance of the gastrointestinal system in the pathogenesis of heart failure

Krack, A., Sharma, R., Figulla, H. R., & Anker, S. D. (2005) · European Heart Journal

Heart Failure Treatment and ManagementAbdominal vascular conditions and treatments

Cited by 280

Effect of empagliflozin in patients with heart failure across the spectrum of left ventricular ejection fraction

Butler, J., Packer, M., Filippatos, G., Ferreira, J. P., Zeller, C., Schnee, J., Brueckmann, M., Pocock, S. J., Zannad, F., & Anker, S. D. (2022) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 264

Hyperkalemia risk with finerenone: results from the FIDELIO-DKD Trial

Agarwal, R., Joseph, A., Anker, S. D., Filippatos, G., Rossing, P., Ruilope, L. M., Pitt, B., Kolkhof, P., Scott, C., Lawatscheck, R., et al. (2022) · Journal of the American Society of Nephrology

Potassium and Related DisordersChronic Kidney Disease and Diabetes

Cited by 262

Neurohumoral activation as a link to systemic manifestations of chronic lung disease

Andreas, S., Anker, S. D., Scanlon, P. D., & Somers, V. K. (2005) · Chest

Chronic Obstructive Pulmonary Disease (COPD) ResearchAsthma and respiratory diseases

Cited by 243

Intestinal Blood Flow in Patients With Chronic Heart Failure

Sandek, A., Swidsinski, A., Schroedl, W., Watson, A., Valentova, M., Herrmann, R., Scherbakov, N., Cramer, L., Rauchhaus, M., Grosse-Herrenthey, A., et al. (2014) · Journal of the American College of Cardiology

Abdominal vascular conditions and treatmentsHeart Failure Treatment and Management

Cited by 239

Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document

Zannad, F., Garcia, A. A., Anker, S. D., Armstrong, P. W., Calvo, G., Cleland, J. G. F., Cohn, J. N., Dickstein, K., Domanski, M. J., Ekman, I., et al. (2013) · European Journal of Heart Failure

Heart Failure Treatment and ManagementStatistical Methods in Clinical Trials

Cited by 231

C-terminal provasopressin (copeptin) is a strong prognostic marker in patients with heart failure after an acute myocardial infarction: results from the OPTIMAAL study

Voors, A. A., von Haehling, S., Anker, S. D., Hillege, H. L., Struck, J., Hartmann, O., Bergmann, A., Squire, I., van Veldhuisen, D. J., Dickstein, K., et al. (2009) · European Heart Journal

Heart Failure Treatment and ManagementAcute Myocardial Infarction Research

Cited by 222

Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy

Seferović, P. M., Tsutsui, H., McNamara, D. M., Ristić, A. D., Basso, C., Bozkurt, B., Cooper, L. T., Filippatos, G., Ide, T., Inomata, T., et al. (2021) · European Journal of Heart Failure

Viral Infections and Immunology ResearchTransplantation: Methods and Outcomes

Cited by 219

Effect of empagliflozin on exercise ability and symptoms in heart failure patients with reduced and preserved ejection fraction, with and without type 2 diabetes

Abraham, W. T., Lindenfeld, J., Ponikowski, P., Agostoni, P., Butler, J., Desai, A. S., Filippatos, G., Gniot, J., Fu, M., Gullestad, L., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 217

Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: An analysis of the PROactive study population

Doehner, W., Erdmann, E., Cairns, R., Clark, A. L., Dormandy, J. A., Ferrannini, E., & Anker, S. D. (2012) · International Journal of Cardiology

Diabetes, Cardiovascular Risks, and LipoproteinsDiabetes Treatment and Management

Cited by 215

Empagliflozin, Health Status, and Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial

Butler, J., Filippatos, G., Jamal Siddiqi, T., Brueckmann, M., Böhm, M., Chopra, V. K., Pedro Ferreira, J., Januzzi, J. L., Kaul, S., Piña, I. L., et al. (2022) · Circulation

Heart Failure Treatment and ManagementCardiovascular Function and Risk Factors

Cited by 206

Lack of evidence of increased mortality among patients with atrial fibrillation taking digoxin: findings from post hoc propensity-matched analysis of the AFFIRM trial

Gheorghiade, M., Fonarow, G. C., van Veldhuisen, D. J., Cleland, J. G. F., Butler, J., Epstein, A. E., Patel, K., Aban, I. B., Aronow, W. S., Anker, S. D., et al. (2013) · European Heart Journal

Atrial Fibrillation Management and OutcomesHeart Failure Treatment and Management

Cited by 192

Invasive Assessment of Bacterial Endotoxin and Inflammatory Cytokines in Patients with Acute Heart Failure

Peschel, T., Schönauer, M., Thiele, H., Anker, S., Schuler, G., & Niebauer, J. (2003) · European Journal of Heart Failure

Sepsis Diagnosis and TreatmentHeart Failure Treatment and Management

Cited by 187

Design and Baseline Characteristics of the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease Trial

Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Nowack, C., Kolkhof, P., Ferreira, A. C., Schloemer, P., Filippatos, G., et al. (2019) · American Journal of Nephrology

Chronic Kidney Disease and DiabetesAcute Kidney Injury Research

Cited by 184

Empagliflozin and health-related quality of life outcomes in patients with heart failure with reduced ejection fraction: the EMPEROR-Reduced trial

Butler, J., Anker, S. D., Filippatos, G., Khan, M. S., Ferreira, J. P., Pocock, S. J., Giannetti, N., Januzzi, J. L., Piña, I. L., Lam, C. S. P., et al. (2021) · European Heart Journal

Heart Failure Treatment and ManagementDiabetes Treatment and Management

Cited by 183

Finerenone reduces new-onset atrial fibrillation in patients with chronic kidney disease and type 2 diabetes

Filippatos, G., Bakris, G. L., Pitt, B., Agarwal, R., Rossing, P., Ruilope, L. M., Butler, J., Lam, C. S. P., Kolkhof, P., Roberts, L., et al. (2021) · Journal of the American College of Cardiology

Atrial Fibrillation Management and OutcomesChronic Kidney Disease and Diabetes

Cited by 153

Glucagon-Like Peptide 1 Receptor Agonists and Heart Failure: The Need for Further Evidence Generation and Practice Guidelines Optimization

Khan, M. S., Fonarow, G. C., McGuire, D. K., Hernandez, A. F., Vaduganathan, M., Rosenstock, J., Handelsman, Y., Verma, S., Anker, S. D., McMurray, J. J. V., et al. (2020) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 139